spiro(3,4-dihydro-2H-1-benzopyran-2,1'-cyclopentane) | 74181-07-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: spiro(3,4-dihydro-2H-1-benzopyran-2,1'-cyclopentane)
• 英文别名: 3,4-Dihydro-2,2-tetramethylene-2H-1-benzopyran；Spiro[3,4-dihydrochromene-2,1'-cyclopentane]
• CAS: 74181-07-0
• 化学式: C₁₃H₁₆O
• 分子量: 188.269
• InChiKey: NORLHXFVNQCDPF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  spiro(3,4-dihydro-2H-1-benzopyran-2,1'-cyclopentane) 在 sodium acetate 、 三氯氧磷 作用下， 反应 1.92h， 生成
  参考文献：
  名称：

  Substituted dihydrobenzopyran and dihydrobenzofuran thiazolidine-2,4-diones as hypoglycemic agents

  摘要：

  A series of dihydrobenzofuran and dihydrobenzopyran thiazolidine-2,4-diones (compounds 3-26) was synthesized from the corresponding aryl aldehydes 1 in two steps. These compounds represent conformationally restricted analogues of the novel hypoglycemic ciglitazone. The series was evaluated by hypoglycemic effects in vitro by measuring stimulation of 2-deoxyglucose uptake in L6 myocytes and stimulation of expression of the glucose transporter protein in 3T3-L1 adipocytes. In vivo hypoglycemic effects were evaluated in the genetically obese ob/ob mouse, and structure-activity relationships are discussed. On the basis of this in vivo potency, we have selected the 2(R)-benzylbenzopyran derivative to be further studied in a clinical setting.

  DOI：

  10.1021/jm00105a050
• 作为产物：
  描述：

  氢化肉桂酸内酯 在 盐酸 作用下， 以 四氢呋喃 为溶剂， 反应 6.0h， 生成 spiro(3,4-dihydro-2H-1-benzopyran-2,1'-cyclopentane)
  参考文献：
  名称：

  A Facile Synthesis of Spirochromanes - 3,4-Dihydrospiro[2H-1-benzopyran-2,1′-cycloalkanes]

  摘要：

  DOI：

  10.1055/s-1980-29000

文献信息

• Tetrahydrobenzopyran derivatives
  申请人：The Upjohn Company

  公开号：US04329459A1

  公开（公告）日：1982-05-11

  The present invention provides novel 8-heteroaryltetrahydrobenzopyrans and analogs thereof. These novel compounds are useful as inhibitors of endoperoxide cyclooxygenase which prevents the conversion of unsaturated fatty acids to endoperoxides. Because of this pharmacological activity, these compounds represent potent platelet aggregation inhibitors.

  本发明提供了新颖的8-杂环芳基四氢苯并吡喃及其类似物。这些新型化合物可用作内过氧化物环氧合酶的抑制剂，从而防止不饱和脂肪酸转化为内过氧化物。由于这种药理活性，这些化合物代表了强效的血小板聚集抑制剂。
• CANNONE P.; BELANGER D.; LEMAY G., SYNTHESIS, 1980, NO 4, 301-303
  作者：CANNONE P.、 BELANGER D.、 LEMAY G.

  DOI：——

  日期：——
• CLARK, DAVID A.;GOLDSTEIN, STEVEN W.;VOLKMANN, ROBERT A.;EGGLER, JAMES F.+, J. MED. CHEM., 34,(1991) N, C. 319-325
  作者：CLARK, DAVID A.、GOLDSTEIN, STEVEN W.、VOLKMANN, ROBERT A.、EGGLER, JAMES F.+

  DOI：——

  日期：——
• US4329459A
  申请人：——

  公开号：US4329459A

  公开（公告）日：1982-05-11
• US7838676B2
  申请人：——

  公开号：US7838676B2

  公开（公告）日：2010-11-23